Bausch Health is rumored to be looking to sell its Bausch + Lomb business, which will ease bankruptcy concerns and upgrade ...

Bausch+Lomb ($BLCO), a contact lens supplier, is exploring a sale to address concerns raised by its lenders like Apollo ...

Bausch + Lomb BLCO. The industry declined 0.6% during this timeframe. The sale, intended to separate both companies, is stuck for quite some time now. Hence, reports of BHC moving forward have ...

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to ...

Eyecare company is working with Goldman Sachs on a deal that would extricate it from its indebted parent, the Financial Times reported The stock of eyecare company Bausch + Lomb Corp. was up 14%on ...

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Bausch + Lomb Corporation (BLCO – Research Report) yesterday and set a ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Blackstone, Advent International and TPG are among a long list of private equity firms studying bids for ...

Bausch + Lomb BLCO shares ended the last trading session 14.5% higher at $17.80. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session.

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Bausch + Lomb, one of the world’s largest contact lens suppliers, is exploring a sale as a way to clean ...

As part of the deal, Bausch + Lomb will help scale commercialization of Trukera’s ScoutPro Osmolarity System, a device that measures tear osmolarity, or the salt content of a person’s tears, to help ...

The Opal platform offers eye care professionals a complementary tool for patients, featuring order tracking, appointment ...